Hepatitis C virus treatment failure:Clinical utility for testing resistance-associated substitutions

查看全文 作　　者：Ezequiel [1]Ridruejo;Matias Javier [2]Pereson;Diego M [3]Flichman;Federico Alejandro Di [2]Lello 机构地区：[1]Hepatology Section,Department of Medicine,Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno“CEMIC”,Ciudad Autonoma de Buenos Aires C1425AS,Unspecified,Argentina;[2]Facultad de Farmacia y Bioquimica,Instituto de Investigaciones en Bacteriologea y Virologea Molecular(IBaViM),Universidad de Buenos Aires,Ciudad Autonoma de Buenos Aires 1113,Argentina;[3]Instituto de Investigaciones Biomedicas en Retrovirus y Sindrome de Inmunodeficiencia Adquirida(INBIRS),Universidad de Buenos Aires,Ciudad Autonoma de Buenos Aires 1113,Argentina 出　　处：《World Journal of Hepatology》索引2021年第13卷第9期,共10页 摘　　要：The hepatitis C virus has a high mutation capacity that leads to the emergence of resistance-associated substitutions(RAS).However,the consequence of resistance selection during new direct-acting antiviral drug(DAA)treatment is not necessarily the therapeutic failure.In fact,DAA treatment has shown a high rate(>95%)of sustained virological response even when high baseline RAS prevalence has been reported.In the context of RAS emergence and high rates of sustained viral response,the clinical relevance of variants harboring RAS is still controversial.Therefore,in order to summarize the data available in international guidelines,we have reviewed the clinical utility of testing RAS in the era of new pangenotypic DAA drugs. 关 键 词：Hepatitis C virus Treatment failure RESISTANCE Direct-acting antiviral